What Вигантол Treats: Main Uses and Benefits

The primary therapeutic function of Вигантол (Colecalciferol) is relevant in contexts involving heightened systemic burden and provides supportive relief for bone and muscle health. The medicine is commonly used to support the body’s use of calcium for healthy bones and muscles and is applied in addressing conditions resulting from deficiency.

---

Therapeutic Applications and Benefits

This medicine is applied across therapeutic domains where additional symptomatic support is needed in situations involving systemic mineral imbalance. It is commonly used across conditions presenting with acute or disruptive episodes of deficiency, such as rickets and osteomalacia. It is also considered relevant in long-term regimens to support the management of bone conditions like osteoporosis and to address hypocalcemia.

In situations involving this imbalance, the medicine supports the process that helps ease the overall symptom burden of these established diseases.

“Supporting the fundamental requirements for bone and muscle health contributes to maintaining functional stability.”

This use addresses symptom clusters that interfere with daily comfort, including muscle weakness (myopathy), persistent fatigue, and diffuse symptoms related to physical discomfort. Supporting the management of the underlying deficit may assist with easing the symptom burden, contributing to improved comfort and functional stability during symptomatic periods.

Quick Fact: Relief for Musculoskeletal Discomfort	Category	Therapeutic Use Focus
Main Conditions	Rickets, Osteomalacia, Vitamin D Deficiency
Symptom Cluster	Muscle weakness, fatigue, skeletal discomfort
Primary Benefit	Supports maintenance of structural and functional stability
Common Context	Prophylaxis; Adjunctive therapy for bone fragility

Regulatory References

1. NIH MedlinePlus overview of Cholecalciferol

Who Can and Cannot Use Vigantol (Colecalciferol)?

This section summarizes the official population eligibility and exclusion criteria for Vigantol, based on government regulatory documentation (e.g., EMA, FDA). It details who is eligible for use and who must not use the medicine.

---

Populations Who Must Not Use (Contraindications)

Use of Vigantol is strictly contraindicated (must not be used) in patients presenting with conditions related to Vitamin D toxicity or hypersensitivity:

• Hypercalcaemia (abnormally high blood calcium levels).
• Hypercalciuria (abnormally high urine calcium excretion).
• Hypervitaminosis D (existing Vitamin D overdose).
• Hypersensitivity (allergy) to the active substance (colecalciferol) or to any of its excipients, such as soybean oil in some formulations.
• Pseudohypoparathyroidism, due to the specific risks of altered Vitamin D metabolism.

---

Populations Requiring Restricted or Conditional Use

Certain populations may use the medicine but require special caution and close medical monitoring:

• Patients with impaired renal function or a history of kidney stones (nephrolithiasis).
• Individuals with sarcoidosis or other granulomatous diseases, due to the risk of increased conversion of Vitamin D to its active form.
• Patients receiving long-term treatment (especially high doses), who require mandatory monitoring of serum calcium levels.
• Pregnant or breastfeeding women may use the medicine to treat an established deficiency, but high doses are generally restricted or unsuitable.

Interactions with other medicines and products

Official regulatory documentation identifies several interaction patterns for Colecalciferol that are categorized based on their effect on the drug's exposure or pharmacodynamic activity.

---

Documented Interaction Patterns

Interaction Type	Interacting Substances/Classes	Regulatory Outcome Description
Additive Effects	Thiazide Diuretics, Calcium Salts, Other Vitamin D Analogues	Increased risk of hypercalcaemia (excessive blood calcium) due to compounding effects on mineral balance.
Reduced Absorption	Ion-Exchange Resins (e.g., Cholestyramine), Mineral Oil Laxatives, Orlistat	Leads to reduced gastrointestinal absorption of the fat-soluble Colecalciferol, decreasing its effectiveness.
Altered Metabolism	Enzyme-Inducing Anticonvulsants (e.g., Phenytoin, Carbamazepine), Rifampicin, Isoniazid	Reduces the effectiveness of Colecalciferol by accelerating its metabolic breakdown or inhibiting its activation.
Toxicity Risk	Cardiac Glycosides (e.g., Digoxin)	Potential hypercalcaemia from Colecalciferol increases the toxicity risk of the cardiac glycoside.

---

Constraints and Separation Rules

Co-administration with other Vitamin D analogues or metabolites is not recommended due to the severe risk of additive hypercalcaemia. For substances that impair absorption, such as ion-exchange resins, official prescribing information recommends allowing as much time as possible between their ingestion and that of Colecalciferol. Population-specific cautions are noted for patients with Sarcoidosis or Severe Renal Insufficiency, as Colecalciferol’s metabolism is altered in these conditions.

How Cholecalciferol Works

Cholecalciferol, a secosteroid and prohormone, is initially metabolized in the liver by the enzyme 25-hydroxylase (CYP2R1) to form calcidiol (25-hydroxyvitamin D3). This circulating metabolite is biologically inactive. It then undergoes a second hydroxylation in the kidney, catalyzed by the 1alpha-hydroxylase enzyme (CYP27B1), yielding the active hormone, calcitriol (1,25-dihydroxyvitamin D3).

Calcitriol functions as an agonist by binding with high affinity to the Vitamin D Receptor (VDR), a nuclear receptor found in target cells, including those of the gastrointestinal tract, bone, and kidney. The resulting calcitriol-VDR complex then heterodimerizes with the Retinoid X Receptor (RXR) and binds to Vitamin D Response Elements (VDREs) on the genome. This molecular interaction modulates the transcription of specific genes, which ultimately results in the controlled regulation of intestinal absorption of calcium and phosphate, and the maintenance of their systemic homeostasis.

How to Use Вигантол (Cholecalciferol) — Official Administration Guidelines

Вигантол (Vigantol), an oily solution containing cholecalciferol (Vitamin D3), is administered strictly according to official regulatory labeling. Proper use requires adherence to precise measurement, specific administration routes, and population-specific dosing schedules.

Administration and Dosage Rules

Administration Scope	Official Labeled Instruction
Route of Administration	Primarily Oral (drops, solution). High-dose administration may sometimes use the Intramuscular (IM) route.
Dosing Schedule	Varies significantly. Prevention typically involves 400 IU to 1,000 IU daily. Treatment of deficiency uses higher, time-limited doses (e.g., 4,000 IU to 6,000 IU daily or 50,000 IU weekly).
Frequency	Daily, Weekly, or Monthly, depending on the therapeutic regimen (maintenance vs. intensive treatment).
Timing	Recommended to be taken with a meal to optimize absorption.

Procedural and Age-Specific Instructions

Administration of the oral solution requires careful execution:

1. Measurement: The prescribed number of drops must be measured precisely using the dropper provided with the package.
2. Intake Method: Drops can be taken directly or mixed with a small amount of liquid or food. For infants, the drops may be placed on a small spoon of milk or puree to ensure the full dose is swallowed.
3. Age-Specific Rules: Dosing is often higher for premature infants (e.g., 1,000 IU daily) and requires careful monitoring and adjustment at 40 weeks corrected age.
4. Missed Dose: If a dose is missed, take it as soon as possible. If it is nearly time for the next scheduled dose, skip the missed one; do not double the dose.

Research evidence / Overview of Studies for Вигантол

This section provides a transparent summary of the official research record for Colecalciferol (Вигантол), describing the types of studies conducted, the outcomes monitored, and where research limitations or uncertainties remain, according to authoritative sources.

Evidence for Specific Clinical Uses

Research on Colecalciferol was studied for three main contexts: addressing bone diseases caused by deficiency, research exploring the use of Colecalciferol for Vitamin D status maintenance, and evaluation in the context of bone health related to conditions like osteoporosis. The quality and type of evidence vary across studies related to these uses.

Research on Rickets and Osteomalacia Treatment

The evidence for Rickets (in children) and Osteomalacia (in adults) is largely based on historical documentation and analyses related to the compound's role in these deficiency diseases, as documented in official regulatory summaries. Studies examined individuals with severe deficiency, monitoring clinical signs of skeletal weakness and outcomes related to systemic or functional imbalance. Findings describe patterns observed in the studies consistent with the monitoring of severe deficiency. Comparative evidence is lacking from recent large-scale randomized controlled trials (RCTs).

Research on Deficiency Prophylaxis

Research exploring the use of Colecalciferol for Vitamin D status maintenance was evaluated in numerous Randomized Controlled Trials (RCTs). Studies focused on outcomes related to systemic or functional imbalance by measuring the concentration of 25-hydroxyvitamin D in the blood, monitoring whether supplementation could achieve and sustain levels above deficiency thresholds over defined time intervals. Findings consistently reported Colecalciferol administration was associated with higher mean serum 25(OH)D concentrations compared to control groups.

Research on Adjunctive Use for Osteoporosis

Colecalciferol was studied for its role in research involving bone fragility, often evaluated in conjunction with calcium. Research involved large-scale RCTs and meta-analyses, enrolling older adults and post-menopausal women studied for bone density changes. Findings from meta-analyses often describe patterns observed in the studies where the combined use of Colecalciferol and calcium was associated with measurements related to fracture incidence. However, trials examining Colecalciferol as a single agent reported greater variability in data related to fracture outcomes. The results apply only to the populations studied.

What is Still Uncertain About the Research

A key area of uncertainty relates to the specific serum 25-hydroxyvitamin D concentration associated with health outcomes beyond bone health, with varying conclusions reported across different scientific bodies. Furthermore, the results of RCTs regarding non-skeletal benefits—such as effects on heart health or certain long-term diseases—have often been mixed findings, and certainty remains low in these areas. For most indications, the existing evidence focuses largely on individuals diagnosed with a deficiency, whereas evidence for those with sufficient Vitamin D levels is more limited.

Key Studies & References

1. Public Assessment Report Scientific discussion Cholecalciferol Teva, 20.000 IU soft capsules (cholecalciferol) - Well-Established Use (WEU) Application (NL)
2. Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended COLECALCIFEROL (EMA)
3. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation
4. Effect of Vitamin D Supplementation on Risk of Fractures and Falls According to Dosage and Interval: A Meta-Analysis

Common questions about Вигантол (FAQ)

Q: What are the symptoms of an overdose or hypervitaminosis D?

Symptoms associated with Vitamin D overdose (Hypervitaminosis D) or elevated blood calcium (Hypercalcaemia) may include general weakness, fatigue, nausea, vomiting, constipation, and headache. Regulatory documents indicate that unmanaged, severe cases of elevated blood calcium are associated with serious complications, including potential damage to the kidneys.

Q: Can I take this medicine with grapefruit juice?

Official drug and food interaction documentation does not list grapefruit juice as a specifically known interacting substance for Colecalciferol. Labeled warnings for this medicine describe known interactions with specific classes of other drugs or products that can affect how the medicine is absorbed or broken down.

Q: Is this medicine safe for women who are pregnant or breastfeeding?

Regulatory documents indicate that use of this medicine during pregnancy and breastfeeding is generally reserved for treating an established Vitamin D deficiency. Official prescribing information advises that high doses are generally restricted or considered unsuitable in these populations.

Q: Can I crush, cut, or chew the solution/drops?

The official administration instructions describe measuring the prescribed number of drops using the dropper and taking them directly or mixed with a small amount of food or liquid. The product documentation does not provide instructions for altering the solution, such as crushing or cutting.

Q: What should I do if the solution looks cloudy or discolored?

Official storage requirements emphasize protecting the product from light and moisture to maintain its stability. If the solution’s appearance changes significantly (e.g., becomes cloudy or discolored), official guidance recommends consulting a healthcare professional or pharmacist. This is because a change in appearance may be associated with the medicine’s quality or effectiveness being compromised.

How to Store and Dispose of Вигантол

Official regulatory guidelines dictate specific storage and disposal requirements to maintain the stability of Вигантол (Cholecalciferol oral solution) and ensure safety.

---

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, not exceeding 25 °C (77 °F) [Source: Official Label]. Do not freeze.
Protection	Keep the container tightly closed in the original outer carton to protect the medicine from light and moisture [Source: Official Label].
In-Use Stability	The product must be discarded 60 days after first opening the bottle [Source: Official Label].
Child Safety	Keep out of the sight and reach of children [Source: Official Label].

---

Disposal

Unused or expired Вигантол must not be thrown away with household waste or disposed of via wastewater. Disposal must comply with local environmental regulations. Users are instructed to consult a pharmacist for guidance on how to safely discard the medicine.